- Antibodies
- New
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Tag
- Peptides
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Amino Acids
- Tag
- Biological Process >
- Proteins
- RNAi
- FL cDNA Clones
- Cell/Tissues/Lysates
LC3 Antibody (APG8A) (I31)Peptide Affinity Purified Rabbit Polyclonal Antibody (Pab)
| Country | United States
Ordering Information
Australia Austria Belgium Brazil Bulgaria Canada China Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Iceland India Indonesia Ireland Israel Italy Japan Korea Latvia Lithuania Luxembourg Macedonia Malaysia Malta Netherlands Norway Pakistan Poland Portugal Romania Serbia Singapore Slovakia Slovenia Spain Sweden Switzerland Taiwan Turkey United Kingdom United States Vietnam Others 
|
|||
|---|---|---|---|---|
| Catalog # | Size | Availability | Price | |
| AP1801c | 0.1 mg 400 ul | In Stock | $ 255.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
- Specification
- Citiations : 0
- Reviews
- Protocols
- Backgrounds
LC3 Antibody (APG8A) (I31) - Product info | |
| Application | IF, WB, IHC
|
| Primary Accession | Q9H492 |
| Other Accession | A6NCE7, Q62625, Q9CQV6, Q9GZQ8, O41515, Q6XVN8, Q91VR7, Q2HJ23 |
| Reactivity | Human |
| Predicted | Bovine, Mouse, Rat |
| Concentration | 0.25 mg/ml |
| Isotype | Rabbit Ig |
| Calculated MW | 14272 Da |
LC3 Antibody (APG8A) (I31) - Additional info | |
| Gene ID 84557 | |
| Other Names MAP1LC3A; Microtubule-associated proteins 1A/1B light chain 3A; Autophagy-related protein LC3 A; Autophagy-related ubiquitin-like modifier LC3 A; MAP1 light chain 3-like protein 1; MAP1A/MAP1B light chain 3 A; Microtubule-associated protein 1 light chain 3 alpha | |
| Target/Specificity This LC3 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 22~51 amino acids from the N-terminal region of human LC3 (APG8a). | |
| Dilution IF~~1:100 WB~~1:50~100WB~~1:1000 IHC~~1:10~50 | |
| Format Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. | |
| Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. | |
| Precautions LC3 Antibody (APG8A) (I31) is for research use only and not for use in diagnostic or therapeutic procedures. | |
LC3 Antibody (APG8A) (I31) - Protein Information | |
| Name MAP1LC3A | |
| Function Involved in formation of autophagosomal vacuoles (autophagosomes) | |
| Cellular Location Cytoplasm, cytoskeleton. Endomembrane system; Lipid-anchor. Cytoplasmic vesicle, autophagosome membrane; Lipid-anchor. Cytoplasmic vesicle, autophagosome. Note=LC3-II binds to the autophagic membranes | |
| Tissue Location Most abundant in heart, brain, liver, skeletal muscle and testis but absent in thymus and peripheral blood leukocytes | |
LC3 Antibody (APG8A) (I31) - Related products
AM1823a: APG8a (MAP1LC3A)-S12 Antibody
AP1801a: LC3 Antibody (APG8A) (N-term)
AP1801b: LC3 Antibody (APG8A) (P45)
AP1801c: LC3 Antibody (APG8A) (I31)
AP1801d: LC3 Antibody (APG8A) (D106)
AP1801e: LC3 Antibody (APG8A) (S12)
AP1801f: LC3 Antibody (APG8A) (S3)
AP1801g: LC3 Antibody (APG8A) (T93/Y99)
AP1801h: LC3 Antibody (APG8A) (T93/Y99)
AP1801i: LC3 Antibody (Isoform B Specific)
AP1805a: Cleaved LC3A Antibody
AP3301a: Phospho-LC3C-S12 Antibody
AP3620a: Phospho-LC3A-T93 Antibody
AP3641a: Phospho-LC3A-S3 Antibody
AP3706a: Phospho-APG8a (MAP1LC3A)-Y99 Antibody
RI13150: MAP1LC3A predesign siRNA
DC04198: Human MAP1LC3A cDNA Clone
BP1801a: LC3 Antibody (APG8a) (N-term) Blocking Peptide
BP1801b: LC3 (APG8a) Antibody (P45) Blocking Peptide
BP1801c: LC3 Antibody (APG8a) (I31) Blocking Peptide
BP1801d: LC3 Antibody (APG8a) (D106) Blocking Peptide
BP1801e: APG8a (MAP1LC3A) Antibody (S12) Blocking Peptide
BP1801f: APG8a (MAP1LC3A) Antibody (S3) Blocking Peptide
BP1801g: APG8a (MAP1LC3A) Antibody (T93/Y99) Blocking Peptide
BP1801h: APG8a (MAP1LC3A) Antibody (T93/Y99) Blocking Peptide
BP1801i: APG8a (MAP1LC3A) Antibody (Isoform b specific) Blocking Peptide
BP1805a: Cleaved-LC3 Antibody (APG8a) Blocking Peptide
BP3301a: Phospho-LC3 (APG8a) - S12 Antibody Blocking Peptide
BP3620a: Phospho-APG8a (MAP1LC3A)-pT93 Antibody Blocking Peptide
BP3641a: Phospho-APG8a (MAP1LC3A)-pS3 Antibody Blocking Peptide
BP3706a: Phospho-APG8a(MAP1LC3A)-Y99 Antibody Blocking Peptide
LC3 Antibody (APG8A) (I31) - Application data
-
_(I31)_U251.jpg)
Fluorescent image of U251 cells stained with LC3 (APG8A) (I31) antibody. U251 cells were treated with Chloroquine (50 μM,16h), then fixed with 4% PFA (20 min), permeabilized with Triton X-100 (0.2%, 30 min). Cells were then incubated with AP1801c LC3 (APG8A) (I31) primary antibody (1:100, 2 h at room temperature). For secondary antibody, Alexa Fluor® 488 conjugated donkey anti-rabbit antibody (green) was used (1:1000, 1h). Nuclei were counterstained with Hoechst 33342 (blue) (10 μg/ml, 5 min). LC3 immunoreactivity is localized to autophagic vacuoles in the cytoplasm of U251 cells.
-
Western blot analysis of LC3 (APG8a) (arrow) using purified Pab (Cat.#AP1801c). 293 cell lysates (2 ug/lane) either nontransfected (Lane 1) or transiently transfected with the LC3 (APG8a) gene (Lane 2) (Origene Technologies).
-
Formalin-fixed and paraffin-embedded human hepatocarcinoma tissue reacted with Autophagy LC3 Antibody (APG8a) (I31) (Cat.#AP1801c), which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated.
_(I31)_U251.jpg)
LC3 Antibody (APG8A) (I31) - Research Areas
Abgent welcomes feedback from its customers.
If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.
Thank you for your support.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
Macroautophagy is the major inducible pathway for the general turnover of cytoplasmic constituents in eukaryotic cells, it is also responsible for the degradation of active cytoplasmic enzymes and organelles during nutrient starvation. Macroautophagy involves the formation of double-membrane bound autophagosomes which enclose the cytoplasmic constituent targeted for degradation in a membrane bound structure, which then fuse with the lysosome (or vacuole) releasing a single-membrane bound autophagic bodies which are then degraded within the lysosome (or vacuole). MAP1A and MAP1B are microtubule-associated proteins which mediate the physical interactions between microtubules and components of the cytoskeleton. These proteins are involved in formation of autophagosomal vacuoles (autophagosomes). MAP1A and MAP1B each consist of a heavy chain subunit and multiple light chain subunits. MAP1LC3a is one of the light chain subunits and can associate with either MAP1A or MAP1B. The precursor molecule is cleaved by APG4B/ATG4B to form the cytosolic form, LC3-I. This is activated by APG7L/ATG7, transferred to ATG3 and conjugated to phospholipid to form the membrane-bound form, LC3-II.
REFERENCES
References for protein: 1.Tanida, I., et al., J. Biol. Chem. 279(35):36268-36276 (2004). 2.He, H., et al., J. Biol. Chem. 278(31):29278-29287 (2003). 3.Mann, S.S., et al., J. Neurosci. Res. 43(5):535-544 (1996). References for U251 cell line: 1. Westermark B.; Pontén J.; Hugosson R. (1973).” Determinants for the establishment of permanent tissue culture lines from human gliomas”. Acta Pathol Microbiol Scand A. 81:791-805. [PMID: 4359449]. 2. Pontén, J.,Westermark B. (1978).” Properties of Human Malignant Glioma Cells in Vitro”. Medical Biology 56: 184-193.[PMID: 359950]. 3. Geng Y.;Kohli L.; Klocke B.J.; Roth K.A.(2010). “Chloroquine-induced autophagic vacuole accumulation and cell death in glioma cells is p53 independent”. Neuro Oncol. 12(5): 473–481.[ PMID: 20406898].
